HRMY - NASDAQ
Harmony Biosciences Holdings, Inc.
$32.10
+0.91%Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
At a Glance
Live SnapshotHarmony Biosciences Holdings, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Net Profit Margin
Strong net margins indicate efficient operations and favorable tax/interest management.
Effective Tax Rate
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Profitability Insight
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
Harmony Biosciences Holdings, Inc. Income Statement
HRMY • NASDAQ
| Harmony Biosciences Holdings, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
868.5M | 714.7M | 582M | 437.9M | 305.4M | 159.7M | 6M | 0.0 | |
GROSS PROFIT | ||||||||
(198.3M) | (156.8M) | (121.2M) | (83.5M) | (55.5M) | (27.7M) | (1.6M) | (184K) | |
670.1M | 557.9M | 460.8M | 354.4M | 249.9M | 132M | 4.4M | -184K | |
OPERATING INCOME | ||||||||
(461.6M) | (367.1M) | (268.8M) | (234.2M) | (162.4M) | (115M) | (150.3M) | (41.4M) | |
(272M) | (221.3M) | (192.7M) | (163.3M) | (132M) | (95.6M) | (80.7M) | (29.1M) | |
(189.6M) | (145.8M) | (76.1M) | (70.9M) | (30.4M) | (19.4M) | (69.6M) | (12.4M) | |
208.5M | 190.8M | 192M | 120.2M | 87.5M | 17M | -145.9M | -41.4M | |
PRE-TAX INCOME | ||||||||
(14.6M) | (17.5M) | (23.8M) | (18.8M) | (24.2M) | (28.2M) | (6.1M) | (0.0) | |
7.3M | 1M | -9M | -15.7M | -24M | -28.2M | -6.1M | 0.0 | |
6.6M | 978K | -18.6M | -15.5M | -50.1M | -53.9M | -6.1M | 1.5M | |
215.1M | 191.8M | 173.4M | 104.7M | 37.4M | -36.9M | -152M | -39.9M | |
NET INCOME | ||||||||
(56.4M) | (46.3M) | (44.5M) | -76.8M | (2.8M) | (0.0) | (0.0) | (0.0) | |
158.7M | 145.5M | 128.9M | 181.5M | 34.6M | -36.9M | -152M | -39.9M |
SEC Filings
HRMY - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 14, 2026 | April 14, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 03, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 |
Related Guides
Continue your HRMY research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.